Search research articles
Contact Us
Filters
Showing results (41-50 of 116) with videos related to
Page
of 12
Sort By:
Neurourology and Urodynamics
|
August 5, 2021
Rodent models of ketamine-induced cystitis
Saki Sultana, Geraint Berger, Ashley Cox, et al.
Clinical Hemorheology and Microcirculation
|
October 12, 2013
Leukocyte-endothelial interactions within the ocular microcirculation in inflammation and infection
N A Al-Banna, J T Toguri, M E M Kelly, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
July 21, 2011
Nonpsychotropic cannabinoids, abnormal cannabidiol and canabigerol-dimethyl heptyl, act at novel cannabinoid receptors to reduce intraocular pressure
Anna-Maria Szczesniak, Yehoshua Maor, Harold Robertson, et al.
Molecular Pharmacology
|
December 25, 2015
Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease
Robert B Laprairie, Amina M Bagher, Melanie E M Kelly, et al.
Molecular Pharmacology
|
April 8, 2016
Antagonism of Dopamine Receptor 2 Long Affects Cannabinoid Receptor 1 Signaling in a Cell Culture Model of Striatal Medium Spiny Projection Neurons
Amina M Bagher, Robert B Laprairie, Melanie E M Kelly, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
September 3, 2011
Indirect sympatholytic actions at β-adrenoceptors account for the ocular hypotensive actions of cannabinoid receptor agonists
Brian D Hudson, Meggie Beazley, Anna-Maria Szczesniak, et al.
British Journal of Pharmacology
|
July 29, 2015
Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor
R B Laprairie, A M Bagher, M E M Kelly, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
July 1, 2006
Ocular hypotensive effects of an intratracheally delivered liposomal delta9-tetrahydrocannabinol preparation in rats
Anna-Maria Szczesniak, Melanie E M Kelly, Sara Whynot, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
June 2, 2018
Methods to Quantify Cell Signaling and GPCR Receptor Ligand Bias: Characterization of Drugs that Target the Endocannabinoid Receptors in Huntington's Disease
Amina M Bagher, Robert B Laprairie, Melanie E M Kelly, et al.
Journal of the National Medical Association
|
September 19, 2000
Correlates of HIV risk-taking behaviors among African-American college students: the effect of HIV knowledge, motivation, and behavioral skills
M Bazargan, E M Kelly, J A Stein, et al.
Page
of 12
Search research articles
Search
Showing results (41-50 of 116) with videos related to
Sort By:
Page
of 12
Neurourology and Urodynamics
|
August 5, 2021
Rodent models of ketamine-induced cystitis
Saki Sultana, Geraint Berger, Ashley Cox, et al.
Clinical Hemorheology and Microcirculation
|
October 12, 2013
Leukocyte-endothelial interactions within the ocular microcirculation in inflammation and infection
N A Al-Banna, J T Toguri, M E M Kelly, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
July 21, 2011
Nonpsychotropic cannabinoids, abnormal cannabidiol and canabigerol-dimethyl heptyl, act at novel cannabinoid receptors to reduce intraocular pressure
Anna-Maria Szczesniak, Yehoshua Maor, Harold Robertson, et al.
Molecular Pharmacology
|
December 25, 2015
Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease
Robert B Laprairie, Amina M Bagher, Melanie E M Kelly, et al.
Molecular Pharmacology
|
April 8, 2016
Antagonism of Dopamine Receptor 2 Long Affects Cannabinoid Receptor 1 Signaling in a Cell Culture Model of Striatal Medium Spiny Projection Neurons
Amina M Bagher, Robert B Laprairie, Melanie E M Kelly, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
September 3, 2011
Indirect sympatholytic actions at β-adrenoceptors account for the ocular hypotensive actions of cannabinoid receptor agonists
Brian D Hudson, Meggie Beazley, Anna-Maria Szczesniak, et al.
British Journal of Pharmacology
|
July 29, 2015
Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor
R B Laprairie, A M Bagher, M E M Kelly, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
July 1, 2006
Ocular hypotensive effects of an intratracheally delivered liposomal delta9-tetrahydrocannabinol preparation in rats
Anna-Maria Szczesniak, Melanie E M Kelly, Sara Whynot, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
June 2, 2018
Methods to Quantify Cell Signaling and GPCR Receptor Ligand Bias: Characterization of Drugs that Target the Endocannabinoid Receptors in Huntington's Disease
Amina M Bagher, Robert B Laprairie, Melanie E M Kelly, et al.
Journal of the National Medical Association
|
September 19, 2000
Correlates of HIV risk-taking behaviors among African-American college students: the effect of HIV knowledge, motivation, and behavioral skills
M Bazargan, E M Kelly, J A Stein, et al.
Page
of 12